Strain Name:

B6.Cg-Mapttm1Hnd Tg(MAPT*S305S)4Gds/Mmjax


Cryopreserved - Ready for recovery     Available at the JAX MMRRC

Please refer to the Mutant Mouse Regional Resource Center (MMRRC) for information about B6.Cg-Mapttm1Hnd Tg(MAPT*S305S)4Gds/Mmjax MMRRC Stock Number 034408.
These double mutant (ht-PAC-305S) mice produce mutated human tau (MAPT), while no endogenous mouse tau (Mapt) is produced. S305S is associated with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP 17). This mutant mouse strain may be useful in studies of tau isoforms in neurodegenerative disease.


The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6.Cg-Mapttm1Hnd Tg(MAPT*S305S)4Gds    (Changed: 22-SEP-11 )
Type Congenic; Targeted Mutation; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
Generation Definitions
Donating Investigator Gerard Schellenberg,   University of Pennsylvania

Homozygotes/Hemizygotes: Mice that are homozygous for the targeted mutation and hemizygous for the transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These double mutant mice produce mutated human tau (MAPT), while no endogenous mouse tau (Mapt) is produced. The ht-PAC-305S transgenic mouse expresses all 6 human tau isoforms with a 3 repeat (3R)-tau to 4 repeat (4R) -tau ratio of approximately 80% 4R-tau to 20% 3R-tau rather than the expected human ratio of 1:1. S305S is associated with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP 17) and is believed to increase exon 10 inclusion during splicing by strengthening the weak exon 10 5' splice site. No gross or microscopic pathologic lesions were observed in these mice. This mutant mouse strain may be useful in studies of tau isoforms in neurodegenerative disease.

Heterozygote: Not evaluated.

The transgenic construct contains the 201 kb P1 artificial chromosome (PAC) 61D6 and includes 5 kb of sequence upstream of the human MAPT promoter and an additional 62 kb downstream of the 3' end of MAPT. The downstream segment also contains the 3' end of the gene KIAA1267, however, human MAPT is the only complete gene in the PAC . The construct includes the "silent" mutation S305S in exon 10 representing an AGT to AGC nucleotide substitution. This mutation does not result in an amino acid substitution. This transgene was microinjected into fertilized C57BL/6 x C3H hybrid oocytes and founder mice were crossed to C57BL/6 mice for 15 generations. Founder line 4 was crossed to B6.129-Mapttm1Hnd mice to generate mice that are homozygous for the targeted mutation and hemizygous for the transgene. The colony was maintained by sibling mating. Upon arrival, mice were bred to C57BL/6J mice to establish the colony.

Control Information

   000664 C57BL/6J
  Considerations for Choosing Controls

Related Strains

View Strains carrying   Mapttm1Hnd     (6 strains)

View Strains carrying other alleles of MAPT     (20 strains)

View Strains carrying other alleles of Mapt     (7 strains)


Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Frontotemporal Dementia; FTD   (MAPT)
Parkinson Disease, Late-Onset; PD   (MAPT)
Parkinson-Dementia Syndrome   (MAPT)
Pick Disease of Brain   (MAPT)
Supranuclear Palsy, Progressive, 1; PSNP1   (MAPT)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Alzheimer's Disease
      Tau (Mapt) mutants
Parkinson's Disease

MAPT related

Neurobiology Research
Alzheimer's Disease
Parkinson's Disease

Mapttm1Hnd related

Neurobiology Research
Alzheimer's Disease
      Tau (Mapt) mutants

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol Mapttm1Hnd
Allele Name targeted mutation 1, Hana N Dawson
Allele Type Targeted (Null/Knockout)
Common Name(s) TAU-;
Mutation Made By Michael Vitek,   Duke University Medical Center
Strain of Origin129X1/SvJ
Gene Symbol and Name Mapt, microtubule-associated protein tau
Chromosome 11
Gene Common Name(s) AI413597; AW045860; DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; Mtapt; PPND; PPP1R103; RNPTAU; TAU; Tau; expressed sequence AI413597; expressed sequence AW045860; pTau;
Molecular Note Exon 1, encoding the translational start site, was replaced by a neomycin selection cassette via homologous recombination. RT-PCR analysis of total brain RNA obtained from homozygous mutant mice showed a lack of transcript produced by the targeted locus.The absence of encoded protein was verified by Western blot analysis of brain homogenates as well as by immunocytochemical analysis of coronal sections. [MGI Ref ID J:78649]
Allele Symbol Tg(MAPT*S305S)4Gds
Allele Name transgene insertion 4, Gerard Schellenberg
Allele Type Transgenic (Humanized sequence, Inserted expressed sequence)
Common Name(s) ht-PAC-305S;
Expressed Gene MAPT, microtubule-associated protein tau, human
Promoter MAPT, microtubule-associated protein tau, human
Molecular Note The transgene contains the complete sequence of human MAPT gene as contained in the P1 artificial chromosome (PAC) 61D6 (Research Genetics, Huntsville, AL). This downstream segment contains the 3 prime end of the gene KIAA1267. MAPT is the only completegene on this PAC. The S305S mutation was introduced into this PAC using a 2- step recombineering process. [MGI Ref ID J:152671]


Genotyping Information

Genotyping Protocols

Tg(MAPT*S305S), Standard PCR
Mapttm1Hnd, Melt Curve Analysis
Mapttm1Hnd, Standard PCR

Helpful Links

Genotyping resources and troubleshooting


References provided by MGI

Selected Reference(s)

McMillan P; Korvatska E; Poorkaj P; Evstafjeva Z; Robinson L; Greenup L; Leverenz J; Schellenberg GD; D'Souza I. 2008. Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol 511(6):788-803. [PubMed: 18925637]  [MGI Ref ID J:152671]

Additional References

Mapttm1Hnd related

Andrews-Zwilling Y; Bien-Ly N; Xu Q; Li G; Bernardo A; Yoon SY; Zwilling D; Yan TX; Chen L; Huang Y. 2010. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci 30(41):13707-17. [PubMed: 20943911]  [MGI Ref ID J:165492]

Baglietto-Vargas D; Kitazawa M; Le EJ; Estrada-Hernandez T; Rodriguez-Ortiz CJ; Medeiros R; Green KN; LaFerla FM. 2014. Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition. Neurobiol Dis 62:407-15. [PubMed: 24176788]  [MGI Ref ID J:207203]

Barreda EG; Avila J. 2011. Tau regulates the subcellular localization of calmodulin. Biochem Biophys Res Commun 408(3):500-4. [PubMed: 21531208]  [MGI Ref ID J:172402]

Dawson HN; Cantillana V; Jansen M; Wang H; Vitek MP; Wilcock DM; Lynch JR; Laskowitz DT. 2010. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169(1):516-31. [PubMed: 20434528]  [MGI Ref ID J:165237]

Dawson HN; Ferreira A; Eyster MV; Ghoshal N; Binder LI; Vitek MP. 2001. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114(Pt 6):1179-87. [PubMed: 11228161]  [MGI Ref ID J:78649]

Fuster-Matanzo A; de Barreda EG; Dawson HN; Vitek MP; Avila J; Hernandez F. 2009. Function of tau protein in adult newborn neurons. FEBS Lett 583(18):3063-8. [PubMed: 19695252]  [MGI Ref ID J:153129]

Gomez de Barreda E; Perez M; Gomez Ramos P; de Cristobal J; Martin-Maestro P; Moran A; Dawson HN; Vitek MP; Lucas JJ; Hernandez F; Avila J. 2010. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis 37(3):622-9. [PubMed: 20004245]  [MGI Ref ID J:158536]

Hall AM; Throesch BT; Buckingham SC; Markwardt SJ; Peng Y; Wang Q; Hoffman DA; Roberson ED. 2015. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease. J Neurosci 35(15):6221-30. [PubMed: 25878292]  [MGI Ref ID J:221673]

Higuchi M; Ishihara T; Zhang B; Hong M; Andreadis A; Trojanowski J; Lee VM. 2002. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 35(3):433-46. [PubMed: 12165467]  [MGI Ref ID J:78400]

Holth JK; Bomben VC; Reed JG; Inoue T; Younkin L; Younkin SG; Pautler RG; Botas J; Noebels JL. 2013. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci 33(4):1651-9. [PubMed: 23345237]  [MGI Ref ID J:193896]

Jimenez-Mateos EM; Gonzalez-Billault C; Dawson HN; Vitek MP; Avila J. 2006. Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J 397(1):53-9. [PubMed: 16536727]  [MGI Ref ID J:116415]

Jin YN; Chen PC; Watson JA; Walters BJ; Phillips SE; Green K; Schmidt R; Wilson JA; Johnson GV; Roberson ED; Dobrunz LE; Wilson SM. 2012. Usp14 deficiency increases tau phosphorylation without altering tau degradation or causing tau-dependent deficits. PLoS One 7(10):e47884. [PubMed: 23144711]  [MGI Ref ID J:192359]

Lei P; Ayton S; Finkelstein DI; Spoerri L; Ciccotosto GD; Wright DK; Wong BX; Adlard PA; Cherny RA; Lam LQ; Roberts BR; Volitakis I; Egan GF; McLean CA; Cappai R; Duce JA; Bush AI. 2012. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18(2):291-5. [PubMed: 22286308]  [MGI Ref ID J:180272]

Li Z; Hall AM; Kelinske M; Roberson ED. 2014. Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol Aging 35(11):2617-24. [PubMed: 24908165]  [MGI Ref ID J:218074]

Luo Y; Nie YJ; Shi HR; Ni ZF; Wang Q; Wang JZ; Liu GP. 2013. PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B. Biochim Biophys Acta 1833(5):1235-43. [PubMed: 23428800]  [MGI Ref ID J:199030]

Meilandt WJ; Yu GQ; Chin J; Roberson ED; Palop JJ; Wu T; Scearce-Levie K; Mucke L. 2008. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 28(19):5007-17. [PubMed: 18463254]  [MGI Ref ID J:135174]

Miller N; Feng Z; Edens BM; Yang B; Shi H; Sze CC; Hong BT; Su SC; Cantu JA; Topczewski J; Crawford TO; Ko CP; Sumner CJ; Ma L; Ma YC. 2015. Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy. J Neurosci 35(15):6038-50. [PubMed: 25878277]  [MGI Ref ID J:221676]

Morris M; Hamto P; Adame A; Devidze N; Masliah E; Mucke L. 2013. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging 34(6):1523-9. [PubMed: 23332171]  [MGI Ref ID J:203367]

Morris M; Koyama A; Masliah E; Mucke L. 2011. Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One 6(12):e29257. [PubMed: 22206005]  [MGI Ref ID J:182343]

Nakamura K; Greenwood A; Binder L; Bigio EH; Denial S; Nicholson L; Zhou XZ; Lu KP. 2012. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 149(1):232-44. [PubMed: 22464332]  [MGI Ref ID J:186082]

Palop JJ; Chin J; Roberson ED; Wang J; Thwin MT; Bien-Ly N; Yoo J; Ho KO; Yu GQ; Kreitzer A; Finkbeiner S; Noebels JL; Mucke L. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55(5):697-711. [PubMed: 17785178]  [MGI Ref ID J:126808]

Pehar M; O'Riordan KJ; Burns-Cusato M; Andrzejewski ME; del Alcazar CG; Burger C; Scrable H; Puglielli L. 2010. Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 9(2):174-90. [PubMed: 20409077]  [MGI Ref ID J:221852]

Rapoport M; Dawson HN; Binder LI; Vitek MP; Ferreira A. 2002. Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99(9):6364-9. [PubMed: 11959919]  [MGI Ref ID J:125456]

Regan P; Piers T; Yi JH; Kim DH; Huh S; Park SJ; Ryu JH; Whitcomb DJ; Cho K. 2015. Tau phosphorylation at serine 396 residue is required for hippocampal LTD. J Neurosci 35(12):4804-12. [PubMed: 25810511]  [MGI Ref ID J:221112]

Reyes JF; Fu Y; Vana L; Kanaan NM; Binder LI. 2011. Tyrosine Nitration within the Proline-Rich Region of Tau in Alzheimer's Disease. Am J Pathol 178(5):2275-85. [PubMed: 21514440]  [MGI Ref ID J:171582]

Roberson ED; Halabisky B; Yoo JW; Yao J; Chin J; Yan F; Wu T; Hamto P; Devidze N; Yu GQ; Palop JJ; Noebels JL; Mucke L. 2011. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31(2):700-11. [PubMed: 21228179]  [MGI Ref ID J:168226]

Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316(5825):750-4. [PubMed: 17478722]  [MGI Ref ID J:121330]

Seward ME; Swanson E; Norambuena A; Reimann A; Cochran JN; Li R; Roberson ED; Bloom GS. 2013. Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J Cell Sci 126(Pt 5):1278-86. [PubMed: 23345405]  [MGI Ref ID J:200462]

Sotiropoulos I; Lopes AT; Pinto V; Lopes S; Carlos S; Duarte-Silva S; Neves-Carvalho A; Pinto-Ribeiro F; Pinheiro S; Fernandes R; Almeida A; Sousa N; Leite-Almeida H. 2014. Selective impact of Tau loss on nociceptive primary afferents and pain sensation. Exp Neurol 261:486-93. [PubMed: 25079367]  [MGI Ref ID J:217564]

Vossel KA; Zhang K; Brodbeck J; Daub AC; Sharma P; Finkbeiner S; Cui B; Mucke L. 2010. Tau reduction prevents Abeta-induced defects in axonal transport. Science 330(6001):198. [PubMed: 20829454]  [MGI Ref ID J:164887]

Yamada K; Cirrito JR; Stewart FR; Jiang H; Finn MB; Holmes BB; Binder LI; Mandelkow EM; Diamond MI; Lee VM; Holtzman DM. 2011. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31(37):13110-7. [PubMed: 21917794]  [MGI Ref ID J:191549]

Zempel H; Luedtke J; Kumar Y; Biernat J; Dawson H; Mandelkow E; Mandelkow EM. 2013. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32(22):2920-37. [PubMed: 24065130]  [MGI Ref ID J:202831]

de Barreda EG; Dawson HN; Vitek MP; Avila J. 2010. Tau deficiency leads to the upregulation of BAF-57, a protein involved in neuron-specific gene repression. FEBS Lett 584(11):2265-70. [PubMed: 20338169]  [MGI Ref ID J:160378]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhile maintaining a live colony, these mice are bred as homozygous for the targeted mutation and hemizygous for the transgene.

Pricing and Purchasing

Supply Notes

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries regarding Terms of Use

Contracts Administration


JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty


In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.